Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA Following Complete Response Letter
核心洞察
Ascelia Pharma (搜索) completed a previously scheduled Type A meeting with the FDA on September 9, 2026, regarding the Complete Response Letter for the Orviglance New Drug Application.
The meeting allowed the company to discuss the issues raised in the CRL and gain clarity on the regulatory path to US approval for Orviglance.
Ascelia will provide an update on the regulatory path forward only after receiving the FDA's official meeting minutes, expected within approximately 30 days.
Ascelia Pharma (搜索) has completed its previously scheduled Type A meeting with the U.S. Food and Drug Administration regarding the Complete Response Letter (CRL) issued for the Orviglance® New Drug Application (NDA). The meeting took place on September 9, 2026, according to the company.
The Type A meeting provided Ascelia with an opportunity to discuss the issues the FDA raised in the CRL and to gain further clarity regarding obtaining regulatory approval for Orviglance in the United States. Type A meetings are typically convened to address disputes or stalled development programs, and in this case the discussion centered on the deficiencies the agency identified in the Orviglance filing.
Regulatory Timeline Hinges on FDA Minutes
Ascelia stated that it will provide an update on the regulatory path forward after receiving the FDA's official meeting minutes. Those minutes are expected within approximately 30 days. The company did not disclose the specific issues raised in the CRL or the content of the September 9 discussion, leaving the next steps for Orviglance contingent on the formal written record of the meeting.
Company Profile and Pipeline
Ascelia Pharma (搜索) is a biotech company focused on orphan oncology treatments. The company describes its strategy as developing and commercializing novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia has two drug candidates in development: Orviglance and Oncoral (搜索).
The company maintains global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm under the ticker ACE.